Ken Griffin Sensei Biotherapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,864 shares of SNSE stock, worth $17,659. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,864
Previous 25,803
7.51%
Holding current value
$17,659
Previous $17,000
47.06%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SNSE
# of Institutions
27Shares Held
2.32MCall Options Held
0Put Options Held
0-
Newtyn Management, LLC New York, NY930KShares$688,3700.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA574KShares$424,6440.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny211KShares$156,1400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA136KShares$100,8750.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX113KShares$83,5460.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $22.7M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...